Janux Therapeutics, Inc.JANXNASDAQ
Loading
Operating Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+30.3%
5Y CAGR+102.8%
Studio
Year-over-Year Change

Expenses from normal business operations (SG&A, R&D, etc.)

3Y CAGR
+30.3%/yr
Annual compound
5Y CAGR
+102.8%/yr
Recent deceleration
Percentile
P100
Near historical high
vs 5Y Ago
34.3x
Strong expansion
Streak
6 yr
Consecutive growthExpanding
PeriodValueYoY Change
2025$165.64M+54.3%
2024$107.38M+35.7%
2023$79.11M+5.7%
2022$74.86M+104.7%
2021$36.57M+657.1%
2020$4.83M+28.1%
2019$3.77M-